Non-pegylated liposomal doxorubicin (Myocet)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity.

Diseases for which it is used

History of changes in EMA indication

  • 2000-07-13: Initial marketing authorization as Myocet.
  • Uncertain date: Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.

Also known as

  • Generic names: liposome-encapsulated doxorubicin citrate, NPLD
  • Brand name: Myocet